Duality Biotherapeutics, Inc.

映恩生物

(Incorporated under the laws of the Cayman Islands with limited liability)

(Stock code: 9606)

(1) CHANGE OF JOINT COMPANY SECRETARY, AUTHORIZED REPRESENTATIVE AND PROCESS AGENT; (2) WAIVER FROM STRICT COMPLIANCE WITH RULES 3.28 AND 8.17 OF THE LISTING RULES; AND (3) CHANGE OF PRINCIPAL PLACE OF BUSINESS IN HONG KONG

CHANGE OF JOINT COMPANY SECRETARY, AUTHORIZED REPRESENTATIVE AND PROCESS AGENT

The board of directors (the "**Board**") of Duality Biotherapeutics (the "**Company**", together with its subsidiaries, the "**Group**") announces that Ms. TSANG Wing Man (曾穎雯) ("**Ms. TSANG**") has resigned from her positions as the joint company secretary of the Company (the "**Joint Company Secretary**"), the authorized representative of the Company (the "**Authorized Representative**") under Rule 3.05 of the Rules Governing the Listing of Securities (the "**Listing Rules**") on The Stock Exchange of Hong Kong Limited (the "**Stock Exchange**") and the authorized representative for acceptance of the service of process and notices on behalf of the Company in Hong Kong under Rule 19.05(2) of the Listing Rules and pursuant to Part 16 of the Companies Ordinance (Chapter 622 of the Laws of Hong Kong) (the "**Process Agent**") with effect from June 26, 2026.

Ms. TSANG has confirmed that she has no disagreement with the Board and there is no matter in relation to her resignations that needs to be brought to the attention of the shareholders of the Company or the Stock Exchange.

The Board is pleased to announce that, Mr. LEUNG Chi Kit (梁志傑) ("**Mr. LEUNG**") has been appointed as the Joint Company Secretary, the Authorized Representative and the Process Agent in replacement of Ms TSANG, with effect from June 26, 2026. Ms. YUAN Jiali (袁佳麗) ("**Ms. YUAN**") will continue to serve as the other Joint Company Secretary.

Mr. LEUNG, who possesses the qualifications required under Rule 3.28 of the Listing Rules, will work closely with, and provide assistance to Ms. YUAN in discharging her duties as a Joint Company Secretary and in gaining the relevant experience as required under Rule 3.28 of the Listing Rules.

The biographical details of Mr. LEUNG and Ms. YUAN are set out below:

Mr. LEUNG is a manager of the Listing Services Department of TMF Hong Kong Limited (a global corporate services provider), has more than 12 years of experience in company secretarial field. He obtained a bachelor's degree in Accounting and Marketing in 2004. Mr. LEUNG is also an associate member of The Hong Kong Chartered Governance Institute and The Chartered Governance Institute in the United Kingdom.

Ms. YUAN Jiali, aged 39, is our head of legal and compliance and has been served as the Joint Company Secretary since April 15, 2025.

Ms. YUAN has nearly 17 years of experience in legal services. Prior to joining our Group, from September 2022 to July 2023, she served as the head of legal in Taizhou EOC Jing'ang Pharmaceutical Co., Ltd. (泰州億騰景昂藥業股份有限公司). From November 2017 to August 2022, she was employed within the group of Fosun International Limited (復星國際有限公司), whose shares are listed on the Stock Exchange (stock code: 656), and Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (上海復星醫藥(集團)股份有限公司), a company listed on both the Stock Exchange (stock code: 2196) and Shanghai Stock Exchange (stock code: 600196), successively serving as legal director, senior legal director, legal executive director and general manager assistant. From April 2011 to May 2017, Ms. YUAN served as an attorney in Beijing Dentons (Shanghai) Law Office (北京大成(上海)律師事務所), focusing on domestic and outbound investment, financing, merger and acquisitions, and commercial dispute resolution. From August 2009 to February 2011, she worked in Rolmax Law Offices.

Ms. YUAN obtained a bachelor's degree in international economics law from Shanghai Institute of Foreign Trade (上海對外貿易學院) (currently known as Shanghai University of International Business and Economics (上海對外經貿大學)) in June 2009, and a master's degree in public policy from the University of Tokyo in Japan in June 2017.

The Board would like to take this opportunity to express its gratitude to Ms. TSANG for her contributions to the Company during her tenure and extend a warm welcome to Mr. LEUNG on his new appointments.

WAIVER FROM STRICT COMPLIANCE WITH RULES 3.28 AND 8.17 OF THE LISTING RULES

Reference is made to the prospectus of the Company dated April 7, 2025, in relation to, among others, the appointment of Ms. YUAN as a Joint Company Secretary. The Stock Exchange has granted a waiver from strict compliance with Rules 3.28 and 8.17 of the Listing Rules (the "**Waiver**") with respect to the appointment of Ms. YUAN as a Joint Company Secretary for a period of three years from the listing date of the Company, i.e. April 15, 2025 (the "**Waiver Period**"), on certain conditions. One of the conditions is that Ms. YUAN must be assisted by Ms. TSANG during the Waiver Period and the Waiver will be revoked immediately if and when Ms. TSANG ceases to provide such assistance during the Waiver Period.

As the conditions of the Waiver can no longer be fulfilled following the resignation of Ms. TSANG, the Company has applied for, and the Stock Exchange has granted, a new waiver (the "**New Waiver**") from strict compliance with the requirements under Rules 3.28 and 8.17 of the Listing Rules in respect of the qualification of Ms. YUAN to act as a Joint Company Secretary of the Company, for the remaining period of the Waiver Period (i.e. from the effective date of appointment of Mr. LEUNG as the Joint Company Secretary to April 14, 2028 (the "**Remaining Waiver Period**") on the following conditions:

(i) Ms. YUAN must be assisted by Mr. LEUNG during the Remaining Waiver Period; and

(ii) the New Waiver could be revoked if there are material breaches of the Listing Rules by the Company.

Before the end of the Remaining Waiver Period, the Company must demonstrate and seek the Stock Exchange's confirmation that Ms. YUAN, having had the benefit of Mr. LEUNG's assistance during the Remaining Waiver Period, has attained the relevant experience and is capable of discharging the functions of company secretary under Rule 3.28 of the Listing Rules such that a further waiver will not be necessary.

The Stock Exchange may withdraw or change the New Waiver if the Company's situation changes, and the New Waiver would be revoked immediately if and when Mr. LEUNG ceases to be the Joint Company Secretary.

CHANGE OF PRINCIPAL PLACE OF BUSINESS IN HONG KONG

The Board further announces that the Company's principal place of business in Hong Kong has been changed to 31/F, Tower Two, Times Square, 1 Matheson Street, Causeway Bay, Hong Kong with effect from June 26, 2026.

By order of the Board
Duality Biotherapeutics, Inc
Dr. ZHU Zhongyuan
Chairman of the Board, Executive Director and Chief Executive Officer

Hong Kong, June 26, 2026

As at the date of this announcement, the Board of the Company comprises (i) Dr. ZHU Zhongyuan, Mr. ZHANG Shaoren and Dr. HUA Haiqing as executive directors; (ii) Mr. CAI Zhiyang and Dr. YU Tao as non-executive directors; and (iii) Mr. XIE Dong, Mr. GAO Fengyong and Ms. CHUAI Shuyin as independent non-executive directors.